Graphical Abstract (IMAGE)
Caption
"For decades, researchers have recognized the importance of helper T cells in generating durable antitumor immunity, yet identifying clinically useful helper signals has remained a major challenge," said Dr. John Letterio, senior corresponding author, Director of the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children’s Hospital, and co-Leader of the Developmental Therapeutics Program of the Case Comprehensive Cancer Center.
"PROTEXI offers a compelling solution by redirecting robust antiviral immune memory toward tumor eradication. What excites us most is the translational promise of this approach. These findings have provided the scientific rationale to advance this platform into first-in-human studies for patients with sarcoma, a disease where innovative immunotherapeutic approaches are urgently needed."
Credit
University Hospitals
Usage Restrictions
N/A
License
Original content